Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04629703 | Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects | PHASE3 | COMPLETED | 280 | — | — | Mar 25, 2021 | Sep 5, 2022 | Aug 18, 2023 | 47 | United States, Argentina +2 |
| Arm | Type | Description |
|---|---|---|
| Fostamatinib (150 mg twice daily for 14 days) + Standard of Care | ACTIVE_COMPARATOR | Fostamatinib (150 mg twice daily for 14 days) + Standard of Care |
| Placebo (twice daily for 14 days) + Standard of Care | PLACEBO_COMPARATOR | Placebo (twice daily for 14 days) + Standard of Care |
| Name | Type | Description |
|---|---|---|
| Fostamatinib | DRUG | Fostamatinib (150 mg twice daily) for 14 days and Standard of Care |
| Placebo | DRUG | Placebo (twice daily) for 14 days and Standard of Care |
Inclusion Criteria: * ≥18 years of age at screening. * The subject or a legally authorized representative has provided written informed consent. * Hospitalized COVID-19 subjects without respiratory failure who are either not receiving any oxygen therapy or are receiving supplemental oxygen via mask...